Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11965182 | 0.94 | CA1 (0.47) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL11953231 | 0.86 | SIRT5 (0.43) | CA1CA2SIRT5ALDH1A1CXCR3 | |
| SCHEMBL11965618 | 0.85 | MTNR1A (0.41) | CA1CA2SIRT5 | |
| SCHEMBL11965619 | 0.84 | MTNR1A (0.41) | CA1CA2SIRT5 | |
| SCHEMBL10253756 | 0.83 | MMP1 (0.40) | CA1CA2MMP1MMP3MMP9 | |
| SCHEMBL10254701 | 0.83 | SIRT5 (0.41) | CA1CA2TDP1MAPTSIRT5 | |
| SCHEMBL10255746 | 0.82 | HDAC4 (0.43) | MMP9 | |
| SCHEMBL11953254 | 0.82 | L3MBTL1 (0.52) | TDP1MAPT | |
| SCHEMBL10255906 | 0.82 | CPA1 (0.45) | CA1CA2 | |
| SCHEMBL10254540 | 0.82 | JAK3 (0.41) | CA1CA2MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196933-A1 | MEXILETINE PRODRUGS | FRANKLIN RICHARD (GB) | 2012-08-02 | — | — | US | disclosed |
| WO-2012085586-A1 | MEXILETINE PRODRUGS | SHIRE, LLC (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196933-A1 | MEXILETINE PRODRUGS | SLC16A1, MTPN, SLC16A3 | CA1 2735/4885CA2 1324/4885TDP1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.